BTIG analyst Sam Eiber lowered the firm’s price target on Merit Medical (MMSI) to $100 from $107 and keeps a Buy rating on the shares as part of a broader research name on Medical Technology. The firm is updating its models to reflect the CMS having announced its proposed rule for the FY27 inpatient prospective payment system which includes, among other things, preliminary commentary and decisions regarding new technology add-on payments, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MMSI:
- Merit Medical management to meet with Barrington
- Merit Medical price target lowered to $90 from $99 at Canaccord
- Merit Medical acquires View Point to expand oncology portfolio
- Merit Medical acquires View Point Medical for $140M
- Merit Medical Systems: Leveraging Medtronic Partnership to Enter High-Growth Interventional Pain Market